Merck’s experimental antibody for RSV reduced infants’ risk of certain lower respiratory infections by 60.4% compared to ...

Pfizer's RSV vaccine was 90% effective at preventing the most severe outcomes in the first-ever vaccination season, the ...

Josh Bilenker and Jeff Engelman's secretive startup Treeline Biosciences has another $421 million, according to a new SEC ...

Amylyx is trying to move forward with its effort to turn its former ALS drug into a treatment for other conditions, and data ...

Shape Therapeutics CEO Francois Vigneault has departed the RNA gene therapy startup, and chief scientific officer David Huss ...

Amicus Therapeutics resolved a patent dispute with Teva on Thursday, allowing Teva to launch a generic version of its Fabry ...

Following a nearly unanimous adcomm against Alfasigma and Intercept Pharmaceuticals’ rare liver disease drug Ocaliva, the FDA ...

After a string of mid-stage failures this year, plus a blow to its major depression commercial plans last year, Sage ...

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...

Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...

Merck KGaA said its doors are open for more M&A, particularly for its manufacturing business, as the company tempers sales ...

BenevolentAI's CEO Joerg Moeller is stepping down effective immediately, the London biotech said Thursday, in the latest ...